TTR and amyloidosis: The recent FDA approval of Patisiran [17] represents a first-of-its-kind RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults and the first ever FDA approval of a siRNA treatment [7].